Authors
Jacqueline Donovan, Yazid N Al Hamarneh, Beata Bajorek, John Papastergiou, Ross T Tsuyuki
Publication date
2020/3
Journal
Canadian Pharmacists Journal/Revue des Pharmaciens du Canada
Volume
153
Issue
2
Pages
84-87
Publisher
SAGE Publications
Description
The global burden of chronic kidney disease (CKD) is increasing, affecting between 3% and 18% of the population when applying the Kidney Disease Improving Global Outcomes (KDIGO) and the Kidney Disease Outcomes Quality Initiative (KDOQI) definitions. 1 In Canada alone, it is estimated to affect approximately 12.5% of the adult population. 2 Similarly, it is estimated to affect 10% of the Australian population. CKD occurs when there is a permanent reduction in renal function (ie, an estimated glomerular filtration rate [eGFR]< 60 mL/min/1.73 m2) or other markers of kidney damage (ie, albuminuria≥ 3 mg/mmol or abnormalities in urine sediment or renal imaging) persisting for more than 3 months. 1 Furthermore, CKD is more broadly an independent risk factor for hypertension and cardiovascular disease, thereby contributing to the high morbidity and mortality rates within the general population. 1 Early …
Total citations
202220232024233
Scholar articles
J Donovan, YN Al Hamarneh, B Bajorek… - … Pharmacists Journal/Revue des Pharmaciens du …, 2020